News
NCEL
2.255
-4.04%
-0.095
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program
TipRanks · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Reuters · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Reuters · 3d ago
NewcelX prices $1.35M equity financing
Seeking Alpha · 3d ago
BUZZ-NewcelX rises after raising funds at premium to boost diabetes program
Reuters · 3d ago
NewcelX Enters Securities Purchase Agreements For Private Placement At $2.75 Per Share, 30% Premium To Last Close
Benzinga · 3d ago
NewcelX prices $1.35 million private placement at 30% premium to market
Reuters · 3d ago
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Barchart · 3d ago
Weekly Report: what happened at NCEL last week (0323-0327)?
Weekly Report · 5d ago
Weekly Report: what happened at NCEL last week (0316-0320)?
Weekly Report · 03/23 10:04
NewcelX AG files Form 3 for Chairman and CEO Ronen Twito
Reuters · 03/18 11:07
NewcelX AG Director Samuel Olivier Files Initial Beneficial Ownership Statement
Reuters · 03/18 11:02
NewcelX AG director Iohan Eran Israel files initial beneficial ownership statement
Reuters · 03/18 10:55
NewcelX AG director Alexander Zwyer files initial beneficial ownership statement
Reuters · 03/18 10:44
Weekly Report: what happened at NCEL last week (0309-0313)?
Weekly Report · 03/16 10:04
NewcelX Forms Eledon Alliance to Accelerate NCEL-101 Diabetes Program
TipRanks · 03/09 11:47
NewcelX announces research agreement with Eledon Pharmaceuticals
TipRanks · 03/09 11:12
NEWCELX AG - COLLABORATION TO INTEGRATE NCEL-101 WITH ELEDON'S TEGOPRUBART (AT-1501)
Reuters · 03/09 11:00
NEWCELX ANNOUNCES STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS TO ADVANCE NCEL-101 PROGRAM FOR TYPE 1 DIABETES
Reuters · 03/09 11:00
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
PR Newswire · 03/09 11:00
More
Webull provides a variety of real-time NCEL stock news. You can receive the latest news about NewcelX Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.